Current advances in immunotherapy in ovarian cancer

被引：7

作者：

Le Saux, Olivia ^{[1
,2
]}

Dubois, Bertrand ^{[2
]}

Stern, Marc-Henri ^{[3
,4
]}

Terme, Magali ^{[5
,6
]}

Tartour, Eric ^{[5
,6
,7
]}

Classe, Jean-Marc ^{[8
]}

Chopin, Nicolas ^{[9
]}

Tredan, Olivier ^{[9
]}

Caux, Christophe ^{[2
]}

Ray-Coquard, Isabelle ^{[9
]}

机构：

[1] Hosp Civils Lyon, Serv Oncol Med, 165 Chemin Grand Revoyet, F-69495 Pierre Benite, France

[2] Univ Claude Bernard Lyon 1, Ctr Rech Cancerol Lyon, CNRS 5286, Ctr Leon Berard,Inserm 1052, F-69008 Lyon, France

[3] Univ Rech PSL, Inst Curie, DNA Repair & Uveal Melanoma DRUM, Inserm U830,Equipe Labellisee Ligue Natl Canc, F-75248 Paris, France

[4] Inst Curie, Dept Biol Tumeurs, Paris, France

[5] PARCC Paris Cardiovasc Res Ctr, Inserm U970, Paris, France

[6] Univ Paris 05, Fac Med, Sorbonne Paris Cite, Paris, France

[7] Hop Europeen Georges Pompidou, AP HP, Serv Immunol Biol, Paris, France

[8] Inst Cancerol Ouest, Dept Chirurg Carcinol, St Herblain, Loire Atlantiqu, France

[9] Ctr Leon Berard, 28 Rue Laennec, F-69008 Lyon, France

来源：

BULLETIN DU CANCER | 2020年 / 107卷 / 04期

关键词：

Ovarian tumors; Therapeutics; Immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; PHASE-III TRIAL; EPITHELIAL OVARIAN; OPEN-LABEL; STAGE-III; T-CELLS; PROGNOSTIC-SIGNIFICANCE; MAINTENANCE THERAPY; BRCA1/2; MUTATION; DOUBLE-BLIND;

D O I：

10.1016/j.bulcan.2019.11.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancers express highly immunogenic tissue-specific antigens. The resulting immune infiltration is a major prognostic factor. There is therefore a strong biological rationale for the development of immunotherapy in ovarian concer. However, based on Phase I and clinical trials data, the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (ICPIs) remains limited in monotherapy in heavily pre-treated patients. Currently, the identification of predictive biomarkers of response and resistance is one of the major areas of research. Identifying effective combination of anti-PD-1 or anti-PD-L1 with other anticancer agents is onother clinical need. Several combinations were evaluated. The association of ICPIs with chemotherapy (anthracydines or carboplotin + paditaxel) is disappointing (JAVELIN studies). The association with PARP inhibitors, anti-ongiogenic agents and CTLA-4 inhibitors seems promising. Other immune therapies such as cell therapies (adoptive transfer of intro-tumor lymphocytes, CAR T cells or vaccines from dendritic cells) could be the future of immunotherapy in ovarian cancer but only early phase studies clinical data is available at this time.

引用

页码：465 / 473

页数：9

共 65 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[4]

[Anonymous], 2018, JCI Insight

[5] Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer [J].

Bindea, Gabriela ;

Mlecnik, Bernhard ;

Tosolini, Marie ;

Kirilovsky, Amos ;

Waldner, Maximilian ;

Obenauf, Anna C. ;

Angell, Helen ;

Fredriksen, Tessa ;

Lafontaine, Lucie ;

Berger, Anne ;

Bruneval, Patrick ;

Fridman, Wolf Herman ;

Becker, Christoph ;

Pages, Franck ;

Speicher, Michael R. ;

Trajanoski, Zlatko ;

Galon, Jerome .

IMMUNITY, 2013, 39 (04) :782-795

[6] Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations [J].

Birkbak, Nicolai Juul ;

Kochupurakkal, Bose ;

Izarzugaza, Jose M. G. ;

Eklund, Aron C. ;

Li, Yang ;

Liu, Joyce ;

Szallasi, Zoltan ;

Matulonis, Ursula A. ;

Richardson, Andrea L. ;

Iglehart, J. Dirk ;

Wang, Zhigang C. .

PLOS ONE, 2013, 8 (11)

[7] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[8] Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer [J].

Buttner, Reinhard ;

Gosney, John R. ;

Skov, Birgit Guldhammer ;

Adam, Julien ;

Motoi, Noriko ;

Bloom, Kenneth J. ;

Dietel, Manfred ;

Longshore, John W. ;

Lopez-Rios, Fernando ;

Penault-Llorca, Frederique ;

Viale, Giuseppe ;

Wotherspoon, Andrew C. ;

Kerr, Keith M. ;

Tsao, Ming-Sound .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) :3867-+

[9] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[10] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].

Cloughesy, Timothy F. ;

Mochizuki, Aaron Y. ;

Orpilla, Joey R. ;

Hugo, Willy ;

Lee, Alexander H. ;

Davidson, Tom B. ;

Wang, Anthony C. ;

Ellingson, Benjamin M. ;

Rytlewski, Julie A. ;

Sanders, Catherine M. ;

Kawaguchi, Eric S. ;

Du, Lin ;

Li, Gang ;

Yong, William H. ;

Gaffey, Sarah C. ;

Cohen, Adam L. ;

Mellinghoff, Ingo K. ;

Lee, Eudocia Q. ;

Reardon, David A. ;

O'Brien, Barbara J. ;

Butowski, Nicholas A. ;

Nghiemphu, Phioanh L. ;

Clarke, Jennifer L. ;

Arrillaga-Romany, Isabel C. ;

Colman, Howard ;

Kaley, Thomas J. ;

De Groot, John F. ;

Liau, Linda M. ;

Wen, Patrick Y. ;

Prins, Robert M. .

NATURE MEDICINE, 2019, 25 (03) :477-+

← 1 2 3 4 5 6 7 →